Top

Published in:

Open Access 01-07-2011 | Review

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

Authors: Gabriela Bindea, Bernhard Mlecnik, Wolf-Herman Fridman, Jérôme Galon

Published in: Seminars in Immunopathology | Issue 4/2011

Abstract

Until now, the anatomic extent of tumor (TNM classification) has been, by far, the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is an essential prognostic factor for patients' disease-free and overall survival. Global analysis of tumor microenvironment showed that the nature, the functional orientation, the density, and the location of adaptive immune cells within distinct tumor regions influence the risk of relapse events. An immune classification of the patients was proposed based on the density and the immune cell location within the tumor. The immune classification has a prognostic value that is superior to the TNM classification, and tumor invasion is statistically dependent on the host immune reaction. Tumor and immunological markers predicted by systems biology methods are involved in the shaping of an efficient immune reaction and can serve as targets for novel therapeutic approaches. Thus, the strength of the immune reaction could advance our understanding of cancer evolution and have important consequences in clinical practice.

Broussard EK, Disis ML (2011) TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol 29:601–603PubMedCrossRef

Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N et al (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327PubMedCrossRef

Sobin L, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York

Weitz J, Koch M, Debus J, Hohler T, Galle PR et al (2005) Colorectal cancer. Lancet 365:153–165PubMedCrossRef

Kumar T, Patel N, Talwar A (2010) Spontaneous regression of thoracic malignancies. Respir Med 104:1543–1550PubMedCrossRef

Bir AS, Fora AA, Levea C, Fakih MG (2009) Spontaneous regression of colorectal cancer metastatic to retroperitoneal lymph nodes. Anticancer Res 29:465–468PubMed

Kalialis LV, Drzewiecki KT, Klyver H (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19:275–282PubMedCrossRef

Bindea G, Mlecnik B, Fridman WH, Pages F, Galon J (2010) Natural immunity to cancer in humans. Curr Opin Immunol 22:215–222PubMedCrossRef

Pages F, Galon J, Fridman WH (2008) The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 84:981–987PubMedCrossRef

10.

Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C et al (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29:1093–1102PubMedCrossRef

11.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef

12.

Galon J, Fridman WH, Pages F (2007) The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 67:1883–1886PubMedCrossRef

13.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G et al (2011) Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 29:610–618PubMedCrossRef

14.

Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666PubMedCrossRef

15.

Xiang R, Lode HN, Gillies SD, Reisfeld RA (1999) T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 163:3676–3683PubMed

16.

Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M et al (2009) In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol 27:5944–5951PubMedCrossRef

17.

Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A et al (2009) Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69:2685–2693PubMedCrossRef

18.

Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 71:1263–1271PubMedCrossRef

19.

Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G et al (2010) Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 138:1429–1440PubMedCrossRef

20.

Salama P, Phillips M, Grieu F, Morris M, Zeps N et al (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186–192PubMedCrossRef

21.

Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949PubMedCrossRef

22.

Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12:5423–5434PubMedCrossRef

23.

Fu J, Xu D, Liu Z, Shi M, Zhao P et al (2007) Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132:2328–2339PubMedCrossRef

24.

Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A et al (2006) High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 108:2957–2964PubMedCrossRef

25.

Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA et al (2008) Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 93:193–200PubMedCrossRef

26.

Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C et al (2006) Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res 12:465–472PubMedCrossRef

27.

Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT et al (2008) High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57:772–779PubMedCrossRef

28.

Michel S, Benner A, Tariverdian M, Wentzensen N, Hoefler P et al (2008) High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability. Br J Cancer 99:1867–1873PubMedCrossRef

29.

Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA et al (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58:449–459PubMedCrossRef

30.

Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC et al (2009) Identification of CD8 + CD25 + Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58:520–529PubMedCrossRef

31.

Badoual C, Hans S, Fridman WH, Brasnu D, Erdman S et al (2009) Revisiting the prognostic value of regulatory T cells in patients with cancer. J Clin Oncol 27:e5–e6PubMedCrossRef

32.

Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H et al (2009) Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA 106:1903–1908PubMedCrossRef

33.

Hoffmann P, Boeld TJ, Eder R, Huehn J, Floess S et al (2009) Loss of FOXP3 expression in natural human CD4 + CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur J Immunol 39:1088–1097PubMedCrossRef

34.

Anraku M, Cunningham KS, Yun Z, Tsao MS, Zhang L et al (2008) Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 135:823–829PubMedCrossRef

35.

Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P et al (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310PubMedCrossRef

36.

de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG et al (2009) Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114:105–110PubMedCrossRef

37.

Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer immunoediting. Annu Rev Immunol 22:329–360PubMedCrossRef

38.

Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61:3932–3936PubMed

39.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213PubMedCrossRef

40.

Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M et al (2008) Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26:4410–4417PubMedCrossRef

41.

Halvorsen TB, Seim E (1989) Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clin Pathol 42:162–166PubMedCrossRef

42.

House AK, Watt AG (1979) Survival and the immune response in patients with carcinoma of the colorectum. Gut 20:868–874PubMedCrossRef

43.

Jass JR (1986) Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 39:585–589PubMedCrossRef

44.

Svennevig JL, Lunde OC, Holter J, Bjorgsvik D (1984) Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 49:375–377PubMedCrossRef

45.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K et al (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491–3494PubMed

46.

Kirkwood JM, Tarhini AA (2009) Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol 27:2583–2585PubMedCrossRef

Title: The prognostic impact of anti-cancer immune response: a novel classification of cancer patients
Authors: Gabriela Bindea
Bernhard Mlecnik
Wolf-Herman Fridman
Jérôme Galon
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 4/2011
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-011-0264-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The prognostic impact of anti-cancer immune response: a novel classification of cancer patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2011

Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy

Contribution of the immune system to the chemotherapeutic response

Prognostic impact of anticancer immune responses: an introduction

Prognostic significance of autoimmunity during treatment of melanoma with interferon

HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page